skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration
  • Close Icon

The decline of cognitive function in the progression of Alzheimer’s disease is well recognized as a primary focus in disease treatment. What may be surprising is the focus on cognition measures in the treatment of other diseases. A Trialtrove search of planned and ongoing clinical trials using the newly added CNS patient segment, Cognitive Function, reveals the diseases with the most activity in evaluating these measures are multiple sclerosis (MS), schizophrenia and Parkinson’s disease (PD).







Why is recognition and treatment of cognition most prevalent in the top three diseases? Recent improvements in evaluation techniques can distinguish cognitive dysfunction from other common symptoms, such as depression and fatigue, thus supporting the utilization of cognitive function outcomes in prospective clinical studies.



The occurrence of severe cognitive dysfunction is prevalent in the secondary progressive form of MS.  Memory dysfunction is also apparent in 20-40% of MS patients, and other cognitive deficits, including impaired planning skills and verbal fluency, are also observed.  For schizophrenia, cognitive decline previously was thought to occur primarily in elderly patients. However significant cognitive impairment is now reported in 75% of all patients assessed (regardless of age), affecting attention, motor skills, executive function, as well as influencing social and functional outcomes. And last, but certainly not least, a reduced efficacy of dopaminergic medications to treat Parkinson’s disease-associated cognitive dysfunction may be integrally associated with depression, thus making it of added importance to track changes in cognitive function in PD trials.1



Considering the current therapeutic trends towards improving cognitive outcomes, the new ‘Cognitive Function’ patient segment offers a valuable competitive intelligence tool for many neurological and psychiatric disease trials.  Contact Citeline to learn more about this newly added information.



1Blonder LX, Slevin JT, Kryscio RJ, Martin CA, Andersen AH, Smith CD, Schmitt FA. Dopaminergic modulation of memory and affective processing in Parkinson depression (2013) Psychiatry Research 210(1):146-149





電話:+81 (0)3 6273 4260